Madrigal Pharmaceuticals (NASDAQ:MDGL) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a research note issued to investors on Wednesday morning,Zacks reports. The firm issued a strong-buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2026 earnings at $0.95 EPS, FY2026 earnings at ($2.37) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at $1.60 EPS, Q3 2027 earnings at $3.13 EPS, Q4 2027 earnings at $4.16 EPS, FY2027 earnings at $8.29 EPS, FY2028 earnings at $29.07 EPS, FY2029 earnings at $43.84 EPS and FY2030 earnings at $71.25 EPS.

Several other equities analysts have also recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and issued a $743.00 price objective (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday. Citigroup increased their target price on Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a “buy” rating in a report on Tuesday. UBS Group restated a “buy” rating and issued a $735.00 price target on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 14th. The Goldman Sachs Group started coverage on Madrigal Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $704.00 price target on the stock. Finally, Barclays dropped their price target on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $706.87.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL traded down $0.47 during mid-day trading on Wednesday, hitting $399.63. 1,087,445 shares of the company’s stock were exchanged, compared to its average volume of 313,609. Madrigal Pharmaceuticals has a 52 week low of $353.54 and a 52 week high of $615.00. The stock’s 50-day simple moving average is $486.74 and its 200-day simple moving average is $497.41. The firm has a market cap of $9.23 billion, a price-to-earnings ratio of -66.83 and a beta of -0.98. The company has a quick ratio of 2.94, a current ratio of 3.20 and a debt-to-equity ratio of 0.65.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $2.92. The business had revenue of $431.27 million during the quarter, compared to analysts’ expectations of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%. During the same period in the previous year, the company posted ($5.08) earnings per share. On average, equities research analysts expect that Madrigal Pharmaceuticals will post -3.78 EPS for the current year.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, CEO William Sibold sold 5,221 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $542.39, for a total value of $2,831,818.19. Following the sale, the chief executive officer owned 197,746 shares of the company’s stock, valued at approximately $107,255,452.94. This trade represents a 2.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bros. Advisors Lp Baker purchased 76,140 shares of the firm’s stock in a transaction dated Friday, November 6th. The stock was acquired at an average price of $384.32 per share, for a total transaction of $29,262,124.80. Following the purchase, the director owned 2,040,682 shares in the company, valued at approximately $784,274,906.24. The trade was a 3.88% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 13,324 shares of company stock worth $7,011,982 over the last three months. Insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Several large investors have recently bought and sold shares of the business. William Blair Investment Management LLC grew its position in Madrigal Pharmaceuticals by 4.0% in the third quarter. William Blair Investment Management LLC now owns 337,035 shares of the biopharmaceutical company’s stock valued at $169,852,000 after acquiring an additional 12,912 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Madrigal Pharmaceuticals by 2.5% in the third quarter. Russell Investments Group Ltd. now owns 50,545 shares of the biopharmaceutical company’s stock worth $25,473,000 after acquiring an additional 1,251 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Madrigal Pharmaceuticals by 3.5% in the third quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 28 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of Madrigal Pharmaceuticals by 17.3% in the third quarter. Maryland State Retirement & Pension System now owns 1,098 shares of the biopharmaceutical company’s stock worth $553,000 after acquiring an additional 162 shares during the last quarter. Finally, Ritholtz Wealth Management acquired a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $200,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.